Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Buchbinder, R.    Giles, G.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study

Rachelle Buchbinder, MBBS(Hons), MSc; Andrew Forbes, PhD; Stephen Hall, MBBS(Hons), BMedSci; Xenia Dennett, PhD; and Graham Giles, PhD, MSc

19 June 2001 | Volume 134 Issue 12 | Pages 1087-1095

Background: The validity and magnitude of an association between myositis and malignant disease continue to be debated. Such issues as the legitimacy of a myositis diagnosis and distinction among myositis subgroups in previous population-based studies remain unresolved.

Objective: To determine the risk for malignant disease in patients with biopsy-proven inflammatory myopathies.

Design: Population-based, retrospective cohort study.

Setting: Victoria, Australia.

Patients: 537 patients in whom a biopsy-positive idiopathic inflammatory myopathy was first diagnosed from 1981 through 1995.

Measurements: Standardized incidence ratios were calculated to compare the incidence of malignant disease in patients with inflammatory myopathy and the general population.

Results: A total of 116 cases of malignant disease were found in 104 patients. Seventy-four cases were identified concurrently with (within 7 days) or after diagnosis of myositis. The highest risk for malignant disease was associated with dermatomyositis (standardized incidence ratio, 6.2 [95% CI, 3.9 to 10.0]). The risk was also increased in polymyositis (standardized incidence ratio, 2.0 [CI, 1.4 to 2.7]), although the relative risk for malignant disease in dermatomyositis compared with polymyositis was 2.4 (CI, 1.3 to 4.2). An increased risk for malignant disease was also found in inclusion-body myositis (standardized incidence ratio, 2.4 [CI, 1.2 to 4.9]). The excess risk for malignant disease diminished with time (standardized incidence ratio, 4.4 [CI, 2.7 to 7.1] in the first year; 3.4 [CI, 2.3 to 5.1] between 1 and 3 years; 2.2 [CI, 1.3 to 3.9] between 3 and 5 years; and 1.6 [CI, 1.0 to 2.6] beyond 5 years [P for trend, 0.002]).

Conclusion: The risk for malignant disease is increased in biopsy-proven dermatomyositis and polymyositis and also appears to be increased in inclusion-body myositis.

Author and Article Information

From Cabrini Medical Centre, Malvern, and Monash University, Melbourne University, and Cancer Control Research Institute of the Anti-Cancer Council of Victoria, Melbourne, Australia.

Grant Support: By a grant from the Arthritis Foundation of Australia.

Requests for Single Reprints: Rachelle Buchbinder, MBBS (Hons), MSc, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144; e-mail, rachelle.buchbinder{at}med.monash.edu.au.

Current Author Addresses: Dr. Buchbinder: Department of Clinical Epidemiology, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.

Dr. Forbes: Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital Campus, Commercial Road, Prahran, Victoria, Australia 3181.

Dr. Hall: Suite 43, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.

Dr. Dennett: State Neuropathology Service, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia 3010.

Dr. Giles: Cancer Epidemiology Centre and Victorian Cancer Registry, Cancer Control Research Institute of the Anti-Cancer Council of Victoria, 100 Drummond Street, Carlton South, Victoria, Australia 3053.

Author Contributions: Conception and design: R. Buchbinder, A. Forbes, S. Hall.

Analysis and interpretation of the data: R. Buchbinder, A. Forbes.

Drafting of the article: R. Buchbinder, A. Forbes.

Critical revision of the article for important intellectual content: R. Buchbinder, A. Forbes, S. Hall, X. Dennett, G. Giles.

Final approval of the article: R. Buchbinder, X. Dennett, G. Giles.

Provision of study materials or patients: R. Buchbinder, X. Dennett, G. Giles.

Statistical expertise: A. Forbes.

Obtaining of funding: R. Buchbinder.

Administrative, technical, or logistic support: R. Buchbinder, G. Giles.

Collection and assembly of data: R. Buchbinder, X. Dennett, G. Giles.

Related articles in Annals:

Summaries for Patients
Associations between Cancer and Inflammation of the Muscles

Annals 2001 134: S12. [Full Text]  

This article has been cited by other articles:

				H. Gunawardena, L. R. Wedderburn, J. North, Z. Betteridge, J. Dunphy, H. Chinoy, J. E. Davidson, R. G. Cooper, N. J. McHugh, and for the Juvenile Dermatomyositis Research Group UK Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis Rheumatology, March 1, 2008; 47(3): 324 - 328. [Abstract] [Full Text] [PDF]

				H. Chinoy, N. Fertig, C. V Oddis, W. E R Ollier, and R. G Cooper The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis Ann Rheum Dis, October 1, 2007; 66(10): 1345 - 1349. [Abstract] [Full Text] [PDF]

				K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito, K. Komura, T. Matsushita, H. Orito, Y. Hamaguchi, K. Yanaba, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy Rheumatology, January 1, 2007; 46(1): 25 - 28. [Abstract] [Full Text] [PDF]

				K. E. Smedby, E. Baecklund, and J. Askling Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2069 - 2077. [Abstract] [Full Text] [PDF]

				I M Bronner, M F G van der Meulen, M de Visser, S Kalmijn, W J van Venrooij, A E Voskuyl, H J Dinant, W H J P Linssen, J H J Wokke, and J E Hoogendijk Long-term outcome in polymyositis and dermatomyositis Ann Rheum Dis, November 1, 2006; 65(11): 1456 - 1461. [Abstract] [Full Text] [PDF]

				M. Gabrilovich, M. Raza, S. Dolan, and T. Raza Paraneoplastic Polymyositis Associated With Squamous Cell Carcinoma of the Lung Chest, June 1, 2006; 129(6): 1721 - 1723. [Abstract] [Full Text] [PDF]

				J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]

				R. P. Polisson, J. T. Crocker, P. R. Mueller, N. L. Harris, and L. M. Duncan Case 29-2005 - A 68-Year-Old Man with Periorbital Swelling, Rash, and Weakness N. Engl. J. Med., September 22, 2005; 353(12): 1275 - 1284. [Full Text] [PDF]

				Z. Amoura, P. Duhaut, D. L. T. Huong, B. Wechsler, N. Costedoat-Chalumeau, C. Frances, P. Cacoub, T. Papo, S. Cormont, Y. Touitou, et al. Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1279 - 1282. [Abstract] [Full Text] [PDF]

				L. Casciola-Rosen, K. Nagaraju, P. Plotz, K. Wang, S. Levine, E. Gabrielson, A. Corse, and A. Rosen Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy J. Exp. Med., February 22, 2005; 201(4): 591 - 601. [Abstract] [Full Text] [PDF]

				J. P. Callen When and How Should the Patient With Dermatomyositis or Amyopathic Dermatomyositis Be Assessed for Possible Cancer? Arch Dermatol, July 1, 2002; 138(7): 969 - 971. [Full Text] [PDF]

				Malignancy and Dermatomyositis: A Neuropathologist's Perspective Journal Watch Dermatology, September 11, 2001; 2001(911): 2 - 2. [Full Text]

				Risk for Malignancy in Inflammatory Myopathies Still Uncertain Journal Watch Neurology, July 26, 2001; 2001(726): 6 - 6. [Full Text]